Epilepsy Outcome at Four Years in a Randomized Clinical Trial Comparing Oral Prednisolone and Intramuscular ACTH in West Syndrome.


Journal

Pediatric neurology
ISSN: 1873-5150
Titre abrégé: Pediatr Neurol
Pays: United States
ID NLM: 8508183

Informations de publication

Date de publication:
06 2021
Historique:
received: 14 07 2020
revised: 01 01 2021
accepted: 24 01 2021
pubmed: 10 4 2021
medline: 27 1 2022
entrez: 9 4 2021
Statut: ppublish

Résumé

This article explores the role of initial treatment on control of spasms and other epilepsies at four years in children previously treated for West syndrome. The Sri Lanka Infantile Spasm Study is a prospective clinical trial evaluating response to intra-muscular adrenocorticotropic hormone (ACTH) versus oral prednisolone. A previous report documented response through age 12 months. This article provides four-year follow-up data. At age four years, 65 of the original 97 were available for follow-up; another 13 had died, and 19 moved and could not be contacted. Of the 65 children, 37 (57%) continued to have seizures and 28 were seizure free. In the 37 children with ongoing epilepsy, 32.4% continued to have spasms, either alone or in combination with other seizure types. The epilepsy types seen in these children were focal epilepsy (59.4%), mixed focal and generalized epilepsy (24%), generalized epilepsy only (10.8%), and uncertain (5%). The majority of those still having epilepsy (66.7%) were controlled on medication. There was no significant difference in the rate of epilepsy or spasms or their control by medication between those treated with ACTH or oral prednisolone. Spasm control at day 14 did not influence the four-year spasm or epilepsy outcome. A majority of children diagnosed with West syndrome continued to have seizures at age four years, although most were controlled on antiseizure medication. The long-term risk of developing epilepsy or its control was the same, regardless of whether ACTH or prednisolone was initially used as treatment.

Sections du résumé

BACKGROUND
This article explores the role of initial treatment on control of spasms and other epilepsies at four years in children previously treated for West syndrome.
METHODS
The Sri Lanka Infantile Spasm Study is a prospective clinical trial evaluating response to intra-muscular adrenocorticotropic hormone (ACTH) versus oral prednisolone. A previous report documented response through age 12 months. This article provides four-year follow-up data.
RESULTS
At age four years, 65 of the original 97 were available for follow-up; another 13 had died, and 19 moved and could not be contacted. Of the 65 children, 37 (57%) continued to have seizures and 28 were seizure free. In the 37 children with ongoing epilepsy, 32.4% continued to have spasms, either alone or in combination with other seizure types. The epilepsy types seen in these children were focal epilepsy (59.4%), mixed focal and generalized epilepsy (24%), generalized epilepsy only (10.8%), and uncertain (5%). The majority of those still having epilepsy (66.7%) were controlled on medication. There was no significant difference in the rate of epilepsy or spasms or their control by medication between those treated with ACTH or oral prednisolone. Spasm control at day 14 did not influence the four-year spasm or epilepsy outcome.
CONCLUSIONS
A majority of children diagnosed with West syndrome continued to have seizures at age four years, although most were controlled on antiseizure medication. The long-term risk of developing epilepsy or its control was the same, regardless of whether ACTH or prednisolone was initially used as treatment.

Identifiants

pubmed: 33836476
pii: S0887-8994(21)00009-6
doi: 10.1016/j.pediatrneurol.2021.01.008
pii:
doi:

Substances chimiques

Glucocorticoids 0
Adrenocorticotropic Hormone 9002-60-2
Prednisolone 9PHQ9Y1OLM

Types de publication

Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

22-26

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Jithangi Wanigasinghe (J)

Faculty of Medicine, Department of Paediatrics, University of Colombo, Colombo, Sri Lanka. Electronic address: jithangi@gmail.com.

Carukshi Arambepola (C)

Faculty of Medicine, Department of Community Medicine, University of Colombo, Colombo, Sri Lanka.

Shalini Sri Ranganathan (SS)

Faculty of Medicine, Department of Pharmacology, University of Colombo, Colombo, Sri Lanka.

Kasun Jayasundara (K)

University Paediatric Unit, Lady Ridgeway Hospital, Colombo, Sri Lanka.

Ashangi Weerasinghe (A)

Faculty of Medicine, Department of Paediatrics, University of Colombo, Colombo, Sri Lanka.

Piyumi Wickramarachchi (P)

Faculty of Medicine, Department of Paediatrics, University of Colombo, Colombo, Sri Lanka.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH